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Brief CommunicationTime-resolved hypothalamic open ﬂow micro-
perfusion reveals normal leptin transport across
the bloodebrain barrier in leptin resistant miceMaximilian Kleinert 1,2,3, Petra Kotzbeck 4, Thomas Altendorfer-Kroath 5, Thomas Birngruber 5,
Matthias H. Tschöp 1,2, Christoffer Clemmensen 1,2,6,*ABSTRACT
Objective: The inability of leptin to suppress food intake in diet-induced obesity, sometimes referred to as leptin resistance, is associated with
several distinct pathological hallmarks. One prevailing theory is that impaired transport of leptin across the bloodebrain barrier (BBB) represents a
molecular mechanism that triggers this phenomenon. Recent evidence, however, has challenged this notion, suggesting that leptin BBB transport
is acquired during leptin resistance.
Methods: To resolve this debate, we utilized a novel cerebral Open Flow Microperfusion (cOFM) method to examine leptin BBB transport in male
C57BL/6J mice, fed a chow diet or high fat diet (HFD) for 20 days.
Results: Basal plasma leptin levels were 3.8-fold higher in HFD-fed mice (p < 0.05). Leptin administration (2.5 mg/kg) elicited similar
pharmacokinetic proﬁles of circulating leptin. However, while leptin reduced food intake by 20% over 22 h in chow-fed mice, it did not affect food
intake in HFD-fed mice. In spite of this striking functional difference, hypothalamic leptin levels, as measured by cOFM, did not differ between
chow-fed mice and HFD-fed mice following leptin administration.
Conclusions: These data suggest that leptin transport across the BBB is not impaired in non-obese leptin resistant mice and thus unlikely to play
a direct role in the progression of pharmacological leptin resistance.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Leptin is a 16 kDa hormone that is secreted from white adipocytes to
signal satiety in the brain. It plays a critical role in the neuroendocrine
regulation of body-weight [1e3]. Null-mutations in the leptin-encoding
gene cause morbid obesity in mice and humans [3,4]. This mono-
genetic obesity is corrected by treatment with recombinant leptin [3,5].
In contrast, common polygenetic obesity [6] is associated with
increased leptin levels and treatment with additional leptin has limited
efﬁcacy to lower body-weight under these circumstances [7e9]. One
prevailing theory is that impaired transport of leptin across the bloode
brain barrier (BBB) plays a central role to this blunted responsiveness
to exogenous leptin e sometimes referred to as leptin resistance. This
theory of a defect in leptin transport across the BBB is rooted in several
observations. First, early studies suggested a lower ratio of leptin in the
cerebral spinal ﬂuid (CSF) to serum leptin in obese humans [10,11],
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www.molecularmetabolism.comhigh-fat diet develop resistance to peripherally administered leptin
before they develop resistance to centrally injected leptin [12,13].
Third, using radiolabeled leptin, researchers found a reduced brain-to-
serum ratio of leptin in obese relative to lean animals [14].
However, leptin resistance describes a complex phenomenon that can
emerge from several distinct entry points. Beyond impairments in
leptin transport, perturbations in the leptin receptor signaling cascade
and disruptions in neural circuits downstream of leptin target neurons
can result in leptin resistance [9,15]. The relative contribution and the
sequential manifestation of these events reported to be associated with
functional leptin resistance remain unclear. Given this uncertainty, we
took advantage of recent methodological advances to speciﬁcally
quantify leptin transport across the BBB in the early stages of diet-
induced leptin resistance (i.e. the inability of exogenous leptin to
suppress food intake). Cerebral Open Flow Microperfusion (cOFM) is a
new in vivo technique that allows for continuous sampling of the
interstitial ﬂuid in brain tissue [16e18], enabling the time-resolvedünchen, German Research Center for Environmental Health (GmbH), Neuherberg,
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Brief Communicationassessment of leptin BBB transport in response to peripheral admin-
istration of recombinant leptin. Using simultaneous measurements of
plasma leptin levels, we generated the ﬁrst combined proﬁle of pe-
ripheral and hypothalamic leptin pharmacokinetics examining diet-
induced leptin resistance in vivo.
2. MATERIALS AND METHODS
2.1. Animals
All animal experiments were approved either by the Danish Animal
Experimental Inspectorate or the Austrian Federal Government
(BMWFW-66.010/0035-WF/V/3b/2017) and were performed in
accordance with Directive 2010/63/EU on the protection of animals
used for scientiﬁc purposes. Mice were housed on a 12:12-h light-dark
cycle at 21e22 C.
2.2. Assessment of pharmacological leptin responsiveness
Fourteen-week-old male C57BL6/J mice were maintained on a stan-
dard rodent chow diet and were single-housed 14 days before a diet
switch, for which mice were randomized to remain on chow diet or to
receive high-fat diet (Research diets, D12331) for 20 days. Mice had
ad libitum access to food and water. At 5 pm on day 20, mice were
injected intraperitoneally with either a bolus of recombinant mouse
leptin (2.5 mg/kg; R&D Systems, USA) or a vehicle solution. Food was
weighed at 2, 6, 14, and 22 h after the injection and the difference to
pre-injection food was deﬁned as food intake.
2.3. Surgery and implantation
Body-weight matched 13 -16-week-old male C57BL6/J mice were
anesthetized with fentanyl (50 mg/kg, Hameln Pharma, Germany),
midazolam (5 mg/kg, Erwo Pharma, Austria) and medetomidin (5 mg/
kg, Orion Pharma, Austria). During stereotactic surgeries and probe
implantation, anesthesia was maintained by constant inhalation of
oxygen (1.5 L/min) and isoﬂurane (0.5% - 1%, Forane, Abbott,
Germany). The cOFM probe was implanted into the hypothalamus
using the following coordinates: AP 0.7 mm, ML -1.5 mm, DV -6 mm
from bregma. For post-surgical pain management, animals received
an antibiotic (Baytril, Bayer, Germany) and rimadyl (Carprofen; Zoetis,
Austria). After surgery, animals recovered for 14 days; then animals
were either kept on chow diet or switched to high-fat diet (Research
diets, D12331) for 20 days.
2.4. Interstitial ﬂuid sampling
Animals were anaesthetized by isoﬂurane (0.5%, 1.5 L/h O2) and
placed on a homeothermic blanket. Body temperature was maintained
at 38 C. The healing dummy was replaced by the sampling inlet,
which was connected to syringe pumps. The cOFM probe was
perfused with artiﬁcial and sterile cerebrospinal ﬂuid (aCSF) in pushe
pull mode. Prior to sampling, the system was equilibrated by a ﬂush
sequence using a ﬂow rate of 2 ml/min for 5 min and a run-in sequence
with 0.5 ml/min for 30 min. During the sampling procedure ﬂow rate
was constant at 0.5 ml/min. After baseline sampling of 30 min, mice
received a bolus of 2.5 mg/kg recombinant mouse leptin (R&D Sys-
tems, USA) intraperitoneally. Thereafter, cOFM samples were collected
over 6 h and stored at 80 C. Corresponding blood samples were
withdrawn through the tail vein into lithium-heparin coated tubes and
centrifuged for 5 min at 2000 g. Plasma was stored at 80 C. After
the last sampling time point, mice were perfused with 10% neutrally
buffered formalin, and brains were carefully dissected out and post-78
 2018 The Authors. Published by Elsevier Gﬁxed overnight. Afterward, brains were kept in 1 PBS. Prior to
sectioning, brains were bathed in 30% sucrose for at least 24 h. 30 mm
thick sections from the entire hypothalamus were made and stained
using a standard hematoxylin and eosin (H&E) protocol to verify proper
probe placement.
2.5. Leptin analysis
Leptin was analyzed with a Leptin ELISA kit (Cat # 22-LEPMS-E01 from
ALPCO, Salem, USA) according to the manufacturer’s instructions.
2.6. Statistical analysis
Data are reported as means  SEM. Graphs were prepared in Prism
version 7.0 (GraphPad Software, San Diego, CA, USA). Data were
analyzed with SigmaPlot version 13.0 (SYSTAT Software, San Jose,
CA, USA). The type of statistical analysis performed is stated in the
ﬁgure legends. p < 0.05 was considered statistically signiﬁcant.
3. RESULTS
3.1. Twenty days of HFD-feeding induces functional leptin
resistance
Compared to chow-fed mice, HFD-fed mice did gain 1.7 g more body-
weight (p < 0.05) but did not reach an obese state by any deﬁnition
(Figure 1A). At 5 pm on day 20, mice were injected with recombinant
leptin (2.5 mg/kg) or vehicle solution. In chow-fed mice, leptin
decreased food intake, measured over 22 h, by w20% (p < 0.05)
compared to vehicle-injected mice (Figure 1B). Leptin decreased body-
weight by 2% compared to the vehicle-injected mice (p < 0.05)
(Figure 1D). In contrast to its effect in chow-fed animals, leptin in-
jection in HFD-fed mice had no effect on food intake or body-weight
(Figure 1C). These results demonstrate that 20 days of HFD feeding
induces functional leptin resistance.
3.2. Hypothalamic availability of exogenous leptin is unaltered by
leptin resistance
Before assessing leptin BBB transport (as described in the methods;
also see schematics in Figure 2A and Suppl. Figure 2), baseline plasma
levels of endogenous leptin were 3.8-fold higher in HFD-fed mice
(p < 0.05; Figure 2B). Following peripheral injection of recombinant
leptin (2.5 mg/kg), circulating leptin levels increased in a similar manner
in chow-fed and HFD-fed mice, reaching a peak of w1200 ng/ml at
60 min after the injection (Figure 2C) (2.5 mg/kg leptin dose, was based
on a dose-titration study (Suppl. Figure 1AeB). The pharmacokinetic
proﬁles of leptin were similar between chow- and HFD-fed mice, which
is also reﬂected by AUCs of 247 42 and 234 39 mg$6-hours$ml1.
These data indicate that during the 6-hour period after injection, the
peripheral leptin bioavailability was comparable in chow- and HFD-fed
mice. In parallel, we analyzed leptin levels over time in interstitial ﬂuid
obtained from the hypothalamus by cOFM sampling (Figure 2A). The
rate of leptin appearance in the hypothalamus was similar between
chow- and HFD-fed mice, with peak concentrations of 4.0e
5.5 ng,ml1 at 60e120 min post-injection. Similar to the peripheral
leptin levels, the overall pharmacokinetic proﬁle of hypothalamic leptin
showed no difference between the two diet groups with AUCs of
949 249 and 1121 204 ng$6-hours$ml1 for chow- and HFD-fed
mice, respectively (p ¼ 0.60, Figure 2F). Collectively, these data indi-
cate that leptin transport across the BBB remains normal in HFD-fed
mice with reduced leptin responsiveness, eliminating that mechanism
as a potential cause for leptin resistance.MOLECULAR METABOLISM 13 (2018) 77e82
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Twenty days of HFD-feeding induces functional leptin resistance. Mice, fed either chow or HFD for 20 days, were intraperitoneally injected with recombinant leptin
or vehicle at 5 pm on day 20. Body-weights on day 0 and on day 20 before the injections were recorded (A). Food weight was determined at indicated times, and cumulative food
intake was calculated (B, C). Body-weights were measured 22 h after the injections and delta (D) body-weight was calculated (D). Data are means  SEM and n ¼ 7e8. Data in
panels A, B and C were analyzed by two-way repeated measures analysis of variance and a Holm-Sidak post-hoc test. In panel D, the differences between vehicle (Veh) and leptin
(Lep) within each diet were analyzed by a two-tailed Student’s t-test. *p < 0.05, **p < 0.01 between vehicle and leptin.4. DISCUSSION
By using a methodological innovation (cOFM) that allows for time-
resolved in vivo sampling of hypothalamic interstitial ﬂuid, we
revealed, for the ﬁrst time, the pharmacokinetic and pharmacodynamic
proﬁles of exogenous leptin in the mouse brain and demonstrated that
transport of leptin across the BBB is not impaired in HFD-induced leptin
resistance.
Since the discovery of leptin in 1994 and the delineation of its anorectic
effects, there has been a considerable interest in transforming these
insights into efﬁcacious anti-obesity pharmacotherapy. However, most
obese individuals are hyperleptinemic and leptin therapy has limited
weight-lowering effects [7]. Recent evidence, however, concludes that
a series of distinct pharmacological compounds can potentiate leptin
signaling and empower its weight-lowering abilities in HFD-induced
obesity [19]. Before such leptin-based combination therapies are
tested in clinical studies, more basic research on leptin physiology and
leptin pharmacology is required.
It is unclear, for instance, whether diminished leptin transport into the
brain is causal or secondary in the development of leptin resistance.
Therefore, we assessed leptin transport in the early phase of HFD-MOLECULAR METABOLISM 13 (2018) 77e82  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comdiet induced leptin resistance, when patent obesity is absent. The
use of cOFM allowed for repeated sampling of hypothalamic inter-
stitial ﬂuids from the same mouse enabling us to assess central leptin
appearance/availability over time. This is an improvement over pre-
vious studies, in which mice are sacriﬁced at each desired time-point
to determine abundance of labeled leptin (e.g. radioactive or ﬂuo-
rescent leptin) in the brain. Thus, we demonstrate that leptin trans-
port across the BBB is normal in the face of functional leptin
resistance after 20 days of HFD.
In contrast to these data, a prevailing model proposes that impaired
leptin transport across the BBB triggers the development of leptin
resistance in obesity [20]. Thus, when it was found that the ratio of
leptin in the CSF to leptin in circulation is lower with obesity [10,11] it
was proposed that this reﬂects a saturation/impairment in leptin
transport across the BBB that drives leptin resistance. Yet, the same
studies showed that total levels of leptin in the CSF are higher with
obesity, indicating the existence of a central component in leptin
resistance. It is an equally plausible explanation that leptin resistance
and resulting central hyperleptinemia trigger adaptations to actually
decrease leptin transport rates across the BBB to lower the abundance
of leptin in the brain. Chronic central hyperleptinemia can causeopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 79
Figure 2: The rate of leptin appearance in the brain is normal in leptin resistant mice. Mice with implanted cOFM probes (see methods) were fed either chow or HFD for 20
days before leptin transport into the brain was assessed (A). Prior to the intraperitoneal injection of recombinant leptin, mixed tail blood was collected to determine baseline plasma
leptin levels (B). Leptin concentrations were then determined in either plasma (C) or interstitial ﬂuid collected from the brain (E) at indicated time-points. Corresponding area under
the curves (AUCs) were calculated (D,F). Data are means  SEM and n ¼ 10 for all groups. Data in panel B, D and E were analyzed with a two-tailed Student’s t-test; data in panel
C and E were analyzed by two-way repeated measures analysis of variance and a Holm-Sidak post-hoc test was performed for the variable ‘time’. *p < 0.05, ***p < 0.001
compared to 0 min #p < 0.05 compared to chow.
Brief Communicationmaladaptations, like hypertension due to leptin’s action on leptin re-
ceptors (LEPRs) in the dorsomedial hypothalamic nucleus [21].
Therefore, our ﬁndings do not preclude that defects in leptin transport
are acquired with chronic obesity (i.e. with chronic leptin resistance).
After 4 weeks of HFD feeding, peripheral leptin injection induced80
 2018 The Authors. Published by Elsevier Ghypothalamic phosphorylation of STAT3 (p-STAT3) [22], a key mediator
of the central action of leptin [23]. In contrast, after 15 weeks of HFD
feeding induction of p-STAT3 by peripheral leptin was impaired [22]. At
the same time, intracerebroventricular (ICV) infusion of leptin
demonstrated that the capacity for p-STAT3 induction is intactMOLECULAR METABOLISM 13 (2018) 77e82
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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following 15 weeks of HFD-feeding [22], indicating that a defect in
leptin transport is present during the later stages of leptin resistance. In
addition, rats selectively bred to develop diet-induced obesity were
functionally leptin resistant at age 4 weeks, despite normal leptin
transport across the BBB [24]. At age 23 weeks, however, leptin BBB
transport was reduced in these rats [24]. Similarly, the ﬁrst study to
demonstrate defects in leptin BBB transport with obesity was con-
ducted in one-year old outbred CD1 mice selected for leaness and
heaviness [14]. Taken together, our data and the above reports sug-
gest that defects in leptin BBB transport are acquired rather than
causal, indicating that central leptin signaling defects are at the root of
the etiology of leptin resistance.
This is supported by animal studies consistently showing that leptin
resistance coincides with defects in signaling transmission distal to
LEPR, even when leptin is administered ICV [25]. The observation that
hyperleptinemia per se, and thus chronically higher LEPR signaling, is
upstream of leptin resistance in obesity could imply a pharmacological
ceiling effect. This is in agreement with elevated hypothalamic pSTAT3
in obesity [26] and the fact that LEPR antagonism increases food intake
and body-weight equally in lean and DIO mice [27] e despite differ-
ences in exogenous leptin sensitivity. Thus, while hypoleptinemia
serves as a hunger-promoting signal, it remains enigmatic if increasing
leptin in the context of a positive energy balance adds relevant cata-
bolic signals [25,28].
Our study has certain limitations. The cOFM method is an invasive
procedure and the probe diameter of 500 mm is relatively large
compared to structures of the mouse brain. Therefore, altered function
due to trauma in the implanted brain area cannot be excluded, which is
why complementary future studies, using less invasive methods, are
warranted to consolidate our conclusions. At the same time, a major
advantage of the cOFM method is that it allows for continuous in vivo
sampling of interstitial ﬂuids in different compartments of the brain
(cortex, striatum, hypothalamus). In previous studies, we have also
demonstrated that the cOFM probe causes minimal tissue trauma
compared to other sampling techniques (e.g., microdialysis)
[16,18,29,30] and given the large pore size of the exchange area of the
cOFM probe, the sampled analytes are not limited to a speciﬁc size or
chemical property. It must also be noted that our study focused on
leptin actions in response to exogenous leptin administration. Thus, we
cannot draw any conclusions about the transport dynamics of
endogenous leptin across the BBB.
In summary, we have created the ﬁrst time-resolved pharmacokinetic-
and pharmacodynamic proﬁle of exogenous leptin in the hypothala-
mus, comparing leptin sensitive and leptin resistant mice. Our data
demonstrate that leptin transport into the hypothalamus is normal in
HFD-induced leptin resistance, thereby removing impaired BBB
transport as a direct cause for diet-induced reductions in leptin
responsiveness.
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